Elanco has finalized its acquisition of Novartis Animal Health.
Elanco president of North American Commercial Operations Rob Aukerman says this acquisition brings together two strong companies with a passion for serving the customer.
Aukerman says Elanco will continue to offer the products its customers trust while significantly investing in the development of new solutions to its customers’ greatest unmet needs.
The company plans to increase research and development investments.
Aukerman says Elanco will continually seek innovative ways it can support its customers’ business.
He says the company will be able to spend more time with individual customers due to the increased technical services that combine Elanco’s analytic and benchmarking tools with on the ground support.
